Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
48.7M
-
Shares change
-
+629K
-
Total reported value, excl. options
-
$212M
-
Value change
-
+$1.57M
-
Put/Call ratio
-
1.44
-
Number of buys
-
57
-
Number of sells
-
-37
-
Price
-
$4.35
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q3 2024
127 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q3 2024.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.7M shares
of 56.1M outstanding shares and own 86.87% of the company stock.
Largest 10 shareholders include T. Rowe Price Investment Management, Inc. (10.7M shares), Bellevue Group AG (8.52M shares), Vestal Point Capital, LP (5.03M shares), NEA Management Company, LLC (4.45M shares), BlackRock, Inc. (3.5M shares), VANGUARD GROUP INC (2.32M shares), TANG CAPITAL MANAGEMENT LLC (1.37M shares), Siren, L.L.C. (1.05M shares), GEODE CAPITAL MANAGEMENT, LLC (945K shares), and ExodusPoint Capital Management, LP (873K shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.